185 related articles for article (PubMed ID: 10561220)
1. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children.
Furman WL; Stewart CF; Poquette CA; Pratt CB; Santana VM; Zamboni WC; Bowman LC; Ma MK; Hoffer FA; Meyer WH; Pappo AS; Walter AW; Houghton PJ
J Clin Oncol; 1999 Jun; 17(6):1815-24. PubMed ID: 10561220
[TBL] [Abstract][Full Text] [Related]
2. A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.
Pitot HC; Adjei AA; Reid JM; Sloan JA; Atherton PJ; Rubin J; Alberts SR; Duncan BA; Denis L; Schaaf LJ; Yin D; Sharma A; McGovren P; Miller LL; Erlichman C
Cancer Chemother Pharmacol; 2006 Aug; 58(2):165-72. PubMed ID: 16328416
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.
Herben VM; Schellens JH; Swart M; Gruia G; Vernillet L; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1999 Jun; 17(6):1897-905. PubMed ID: 10561231
[TBL] [Abstract][Full Text] [Related]
4. Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors.
Furman WL; Crews KR; Billups C; Wu J; Gajjar AJ; Daw NC; Patrick CC; Rodriguez-Galindo C; Stewart CF; Dome JS; Panetta JC; Houghton PJ; Santana VM
J Clin Oncol; 2006 Feb; 24(4):563-70. PubMed ID: 16446328
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of irinotecan in pediatric patients with malignant solid tumors.
Mugishima H; Matsunaga T; Yagi K; Asami K; Mimaya J; Suita S; Kishimoto T; Sawada T; Tsuchida Y; Kaneko M
J Pediatr Hematol Oncol; 2002 Feb; 24(2):94-100. PubMed ID: 11990713
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors.
Rodriguez-Galindo C; Crews KR; Stewart CF; Furman W; Panetta JC; Daw NC; Cain A; Tan M; Houghton PH; Santana VM
Cancer Chemother Pharmacol; 2006 Jan; 57(1):15-24. PubMed ID: 16001174
[TBL] [Abstract][Full Text] [Related]
7. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
Rowinsky EK; Johnson TR; Geyer CE; Hammond LA; Eckhardt SG; Drengler R; Smetzer L; Coyle J; Rizzo J; Schwartz G; Tolcher A; Von Hoff DD; De Jager RL
J Clin Oncol; 2000 Sep; 18(17):3151-63. PubMed ID: 10963644
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.
Wagner LM; Crews KR; Iacono LC; Houghton PJ; Fuller CE; McCarville MB; Goldsby RE; Albritton K; Stewart CF; Santana VM
Clin Cancer Res; 2004 Feb; 10(3):840-8. PubMed ID: 14871959
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
10. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Soepenberg O; Dumez H; Verweij J; de Jong FA; de Jonge MJ; Thomas J; Eskens FA; van Schaik RH; Selleslach J; Ter Steeg J; Lefebvre P; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
Clin Cancer Res; 2005 Feb; 11(4):1504-11. PubMed ID: 15746053
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of oral irinotecan against neuroblastoma xenografts.
Thompson J; Zamboni WC; Cheshire PJ; Richmond L; Luo X; Houghton JA; Stewart CF; Houghton PJ
Anticancer Drugs; 1997 Apr; 8(4):313-22. PubMed ID: 9180383
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of irinotecan administered on a weekly schedule in pediatric patients.
Bomgaars L; Kerr J; Berg S; Kuttesch J; Klenke R; Blaney SM
Pediatr Blood Cancer; 2006 Jan; 46(1):50-5. PubMed ID: 15768380
[TBL] [Abstract][Full Text] [Related]
13. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
DuBois SG; Marachelian A; Fox E; Kudgus RA; Reid JM; Groshen S; Malvar J; Bagatell R; Wagner L; Maris JM; Hawkins R; Courtier J; Lai H; Goodarzian F; Shimada H; Czarnecki S; Tsao-Wei D; Matthay KK; Mosse YP
J Clin Oncol; 2016 Apr; 34(12):1368-75. PubMed ID: 26884555
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of irinotecan in pediatric patients: a pediatric oncology group study.
Blaney S; Berg SL; Pratt C; Weitman S; Sullivan J; Luchtman-Jones L; Bernstein M
Clin Cancer Res; 2001 Jan; 7(1):32-7. PubMed ID: 11205914
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts.
Thompson J; Zamboni WC; Cheshire PJ; Lutz L; Luo X; Li Y; Houghton JA; Stewart CF; Houghton PJ
Clin Cancer Res; 1997 Mar; 3(3):423-31. PubMed ID: 9815701
[TBL] [Abstract][Full Text] [Related]
16. Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors.
McGregor LM; Stewart CF; Crews KR; Tagen M; Wozniak A; Wu J; McCarville MB; Navid F; Santana VM; Houghton PJ; Furman WL; Rodriguez-Galindo C
Pediatr Blood Cancer; 2012 Mar; 58(3):372-9. PubMed ID: 21509928
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan.
Ma MK; Zamboni WC; Radomski KM; Furman WL; Santana VM; Houghton PJ; Hanna SK; Smith AK; Stewart CF
Clin Cancer Res; 2000 Mar; 6(3):813-9. PubMed ID: 10741701
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study.
Wagner LM; Villablanca JG; Stewart CF; Crews KR; Groshen S; Reynolds CP; Park JR; Maris JM; Hawkins RA; Daldrup-Link HE; Jackson HA; Matthay KK
J Clin Oncol; 2009 Mar; 27(8):1290-6. PubMed ID: 19171709
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients.
Chang TC; Shiah HS; Yang CH; Yeh KH; Cheng AL; Shen BN; Wang YW; Yeh CG; Chiang NJ; Chang JY; Chen LT
Cancer Chemother Pharmacol; 2015 Mar; 75(3):579-86. PubMed ID: 25577133
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients.
Takimoto CH; Morrison G; Harold N; Quinn M; Monahan BP; Band RA; Cottrell J; Guemei A; Llorens V; Hehman H; Ismail AS; Flemming D; Gosky DM; Hirota H; Berger SJ; Berger NA; Chen AP; Shapiro JD; Arbuck SG; Wright J; Hamilton JM; Allegra CJ; Grem JL
J Clin Oncol; 2000 Feb; 18(3):659-67. PubMed ID: 10653882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
